FEASIBILITY AND BENEFIT OF MOLECULARLY-INFORMED ENROLLMENT INTO EARLY PHASE CLINICAL TRIALS FOR PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

Background: Patients with relapsed or refractory diffuse large B cell lymphoma (r/r DLBCL) often do poorly with conventional salvage chemotherapy regimens. Next-generation sequencing (NGS) panels can identify recurrent molecular abnormalities, which can help to orient patient's treatement (pts) for potential molecularly oriented therapies or appropriated clinical trials with investigational targeted therapies. We aimed to evaluate whether...